Gut Bacteria Regulate Intestinal Motor Circuits by Metabolizing Sex Hormones

Why It Matters

The discovery reveals a microbiome‑hormone‑neural axis that can be targeted to treat irritable bowel syndrome and other motility disorders, especially those with gender disparities. It positions bacterial β‑glucuronidase as a novel drug target for modulating gut transit.

Key Takeaways

• Bacterial β‑glucuronidase reactivates glucuronated androgens in colon
• Reactivated androgens bind AR in NOS1+ enteric neurons
• Germ‑free mice lose androgen‑dependent gut motility
• GUS inhibition reduces intestinal transit in male mice
• Microbiome‑hormone axis offers therapeutic target for IBS

Pulse Analysis

The gut microbiome has emerged as a central regulator of host physiology, influencing metabolism, immunity, and even behavior. Recent evidence now places it at the heart of gastrointestinal motility, a function traditionally attributed to the enteric nervous system (ENS) and hormonal cues. Androgens, the primary male sex hormones, have long been known to accelerate intestinal transit, yet the precise cellular pathways remained elusive. By integrating microbiology with neurobiology, scientists have begun to map how microbial enzymes reshape hormone availability within the gut lumen, setting the stage for a neuroendocrine feedback loop that governs peristalsis.

In a series of mouse studies, investigators demonstrated that β‑glucuronidase (GUS) enzymes produced by resident bacteria cleave glucuronated androgen conjugates, converting them back into active forms capable of binding androgen receptors (AR) on NOS1‑positive enteric neurons. Fluorescent microscopy revealed that AR expression in these neurons disappears in germ‑free animals or after pharmacologic GUS inhibition, directly linking bacterial activity to neuronal hormone signaling. Functional assays showed that loss of this reactivation blunts intestinal transit, confirming that the bacterial‑mediated hormone pool is not merely a by‑product but a driver of motility. The work bridges a critical gap between microbial metabolism and the ENS, highlighting a previously unappreciated layer of control over gut function.

Clinically, the findings have immediate relevance for disorders such as irritable bowel syndrome (IBS), where altered hormone levels and dysbiosis often coexist. Targeting bacterial GUS activity—either through selective inhibitors or probiotic strategies—could restore normal androgen signaling and improve transit times without systemic hormone therapy. Moreover, the sex‑specific nature of androgen effects suggests a pathway to address gender disparities in gastrointestinal disease prevalence. Future research will need to validate these mechanisms in humans and explore how diet, antibiotics, or microbiome‑modulating interventions influence the gut‑brain‑hormone axis, potentially opening a new frontier in personalized GI therapeutics.